Comparing Tarsus Pharmaceuticals (NASDAQ:TARS) & Gilead Sciences (NASDAQ:GILD)

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) and Gilead Sciences (NASDAQ:GILDGet Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares Tarsus Pharmaceuticals and Gilead Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals -324.99% -31.56% -28.14%
Gilead Sciences 15.03% 42.92% 13.59%

Analyst Recommendations

This is a summary of recent ratings for Tarsus Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals 0 0 3 1 3.25
Gilead Sciences 1 9 4 0 2.21

Tarsus Pharmaceuticals presently has a consensus target price of $52.75, suggesting a potential upside of 256.42%. Gilead Sciences has a consensus target price of $73.53, suggesting a potential upside of 12.09%. Given Tarsus Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Gilead Sciences.

Volatility and Risk

Tarsus Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Institutional and Insider Ownership

87.8% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.6% of Gilead Sciences shares are owned by institutional investors. 33.1% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tarsus Pharmaceuticals and Gilead Sciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tarsus Pharmaceuticals $57.03 million 6.92 -$13.83 million ($2.70) -5.48
Gilead Sciences $27.31 billion 3.01 $6.23 billion $3.28 20.00

Gilead Sciences has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Tarsus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.